Legislation & Regulation

On February 26, 2018, AMCP joined 11 organizations in letter to the OIG in support of establishing a safe harbor provision that would encourage the development of additional value-based contracts for the Medicare and Medicaid populations.

Press Release: Academy of Managed Care Pharmacy (AMCP) CEO Susan A. Cantrell, RPh, CAE, issued the following statement on President Trump’s budget proposal for fiscal year 2019.

AMCP CEO Blog: The FDA approved 46 novel drugs in 2017, a 21-year high. However, it could take as long as six months for some of these groundbreaking medicines to reach patients.

AMCP letter to Majority Leader McConnell, Leader Schumer, Speaker Ryan, and Leader Pelosi

On February 1, 2018, CMS released its 2019 Draft Call Letter. AMCP prepared in initial summary of the highlights contained in the Draft Call Letter. Of particular interest to AMCP members, CMS proposed new strategies for identifying potential opioid abuse which will work with the proposed codification of the current Opioid Monitoring System (OMS) under the Comprehensive Addiction and Recovery Act of 2015 (CARA).

On January 30, 2018, AMCP delivered remarks to the FDA at an opioid policy steering committee meeting. AMCP commended the FDA for establishing the OPSC and for seeking public input to help identify key areas of focus that the FDA can address. AMCP focused on the following three areas; REMS; Labeling, Packaging, Storage, and Disposal; and Additional Focus Areas where AMCP feels that the FDA can be actively involved in combating the opioid epidemic.

The Academy of Managed Care Pharmacy (AMCP) thanks the FDA for the opportunity to provide comments before the Opioid Policy Steering Committee. AMCP commends the FDA for establishing the OPSC and for seeking public input to help identify key areas of focus that the FDA can address.

Press Release: AMCP Praises the House E&C Subcommittee on Health for Advancing H.R. 2026 ‘Pharmaceutical Information Exchange (PIE) Act of 2017’

The Academy of Managed Care Pharmacy (AMCP) is writing to express concerns with specific provisions of House Bill 4472 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists.

AMCP submitted comments to CMS in response to its proposed rule for technical changes to the Medicare Prescription Drug Benefit Program. AMCP offered comments on the following areas of the proposed rule: drug management programs, Medication Therapy Management, benefit design & utilization management, health information technology & data interoperability, and fraud, waste, & abuse.